Granules India's Chantilly facility has successfully passed the US FDA's cGMP audit, despite four minor observations being made during the process. Fortunately, no data integrity concerns were identified in their operations.

Granules Life Sciences has received a Voluntary Action Indicated (VAI) status from the US FDA following an inspection, which focused on current Good Manufacturing Practices (cGMP) and pre-approval inspections. This classification does not suggest any regulatory action and allows for increased production capabilities at Granules Life Sciences.

Granules company reports that the recent FDA inspection resulted in a voluntary action classification. Following the inspection, the FDA decided not to take any additional regulatory actions.

Despite a minor decline during today's session, Granules India exhibits a positive outlook with strong moving averages and MACD indicators suggesting promising medium-term potential.